Network News

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

New AI System Provides Treatment Recommendations for Complex Blood Cancers

New AI System Provides Treatment Recommendations for Complex Blood Cancers

Coaching for Robots: Jens Kober brings people and machines together

Coaching for Robots: Jens Kober brings people and machines together

Vaccine Against Brain Tumors Shows Promising Long-Term Results

Vaccine Against Brain Tumors Shows Promising Long-Term Results

VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

LEEI-Platform eFIT is Available to Industry and Research

LEEI-Platform eFIT is Available to Industry and Research

Dr. Felix Kommoss awarded the 2026 Rudolf Virchow Prize

Dr. Felix Kommoss awarded the 2026 Rudolf Virchow Prize

Large-scale microbiome study identifies robust colorectal cancer signature

Large-scale microbiome study identifies robust colorectal cancer signature